Investor Relation
Information transparency and trust in peers
Investor Relation
13
2026-03
Announcement Notice of Board Meeting
04
2026-03
Overseas Regulatory Announcement-Announcement on Entacapone Tablets having obtained the Drug Registration Certificate
04
2026-03
Overseas Regulatory Announcement-Announcement on Saxagliptin and Metformin Hydrochloride Sustained-release Tablets of Subsidiary Having Obtained the Drug Registration Certificate
02
2026-03
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2026
09
2026-02
Overseas Regulatory Announcement-Announcement on Glucosamine Sulfate Capsules for Suspension having obtained the Drug Registration Certificate
06
2026-02
The Termination of the Equity Acquisition Intention Agreement
02
2026-02
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026
14
2026-01
Next Day Disclosure Returns
05
2026-01
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
31
2025-12
Terms of Reference of the Remuneration and Appraisal Committee under the Board of Directors
总条数: 87